Praxis Precision Medicines, Inc.
PRAXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal. With a market capitalization of $7.06B, it sits in mid-cap territory. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide.
Market Cap
$7.06B
Beta
2.81
P/E (TTM)
—
P/E (Fwd)
-26.62
EPS (TTM)
$-12.95
EPS (Fwd)
$-9.50
ROE
-38.9%
ROA
-25.7%
Cash
$758.6M
Total Debt
$1.1M
Free CF
-$199.4M
52W Change
36.0%
Annual Financials
Cash vs Debt
Where PRAX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, PRAX finished 23.75% below its 150-day moving average ($317.07) and 23.42% below its 200-day moving average ($315.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRAX overbought or oversold?
At the October 19, 2026 close, PRAX's RSI(14) was 28.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Praxis Precision Medicines, Inc. holds $758.6M in cash against $1.1M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$199.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -38.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Praxis Precision Medicines, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, PRAX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing PRAX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.